Switch theme
Sign up to access all valuation multiples
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MedCap has a last 12-month revenue (LTM) of $202M and a last 12-month EBITDA of $42.0M.
In the most recent fiscal year, MedCap achieved revenue of $189M and an EBITDA of $41.4M.
MedCap expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MedCap valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $202M | XXX | $189M | XXX | XXX | XXX |
| Gross Profit | $117M | XXX | $111M | XXX | XXX | XXX |
| Gross Margin | 58% | XXX | 59% | XXX | XXX | XXX |
| EBITDA | $42.0M | XXX | $41.4M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $28.8M | XXX | $25.2M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $22.0M | XXX | $21.7M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, MedCap's stock price is SEK 523 (or $55).
MedCap has current market cap of SEK 7.8B (or $818M), and EV of SEK 7.8B (or $821M).
See MedCap trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $821M | $818M | XXX | XXX | XXX | XXX | $1.84 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, MedCap has market cap of $818M and EV of $821M.
MedCap's trades at 4.3x EV/Revenue multiple, and 19.8x EV/EBITDA.
Equity research analysts estimate MedCap's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MedCap has a P/E ratio of 37.2x.
See valuation multiples for MedCap and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $818M | XXX | $818M | XXX | XXX | XXX |
| EV (current) | $821M | XXX | $821M | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 19.5x | XXX | 19.8x | XXX | XXX | XXX |
| EV/EBIT | 28.5x | XXX | 32.6x | XXX | XXX | XXX |
| EV/Gross Profit | 7.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 37.2x | XXX | 37.7x | XXX | XXX | XXX |
| EV/FCF | 63.9x | XXX | 26.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMedCap's last 12 month revenue growth is 11%
MedCap's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.3M for the same period.
MedCap's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MedCap's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MedCap and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MedCap acquired XXX companies to date.
Last acquisition by MedCap was XXXXXXXX, XXXXX XXXXX XXXXXX . MedCap acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is MedCap headquartered? | MedCap is headquartered in Sweden. |
| How many employees does MedCap have? | As of today, MedCap has 270 employees. |
| Who is the CEO of MedCap? | MedCap's CEO is Mr. Anders Dahlberg. |
| Is MedCap publicy listed? | Yes, MedCap is a public company listed on STO. |
| What is the stock symbol of MedCap? | MedCap trades under MCAP ticker. |
| When did MedCap go public? | MedCap went public in 2004. |
| Who are competitors of MedCap? | Similar companies to MedCap include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of MedCap? | MedCap's current market cap is $818M |
| What is the current revenue of MedCap? | MedCap's last 12 months revenue is $202M. |
| What is the current revenue growth of MedCap? | MedCap revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of MedCap? | Current revenue multiple of MedCap is 4.1x. |
| Is MedCap profitable? | Yes, MedCap is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MedCap? | MedCap's last 12 months EBITDA is $42.0M. |
| What is MedCap's EBITDA margin? | MedCap's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of MedCap? | Current EBITDA multiple of MedCap is 19.5x. |
| What is the current FCF of MedCap? | MedCap's last 12 months FCF is $12.9M. |
| What is MedCap's FCF margin? | MedCap's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of MedCap? | Current FCF multiple of MedCap is 63.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
